Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-216 in Friedreich Ataxia
NCT05285540Phase 1Completed
- Sponsor
- Design Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich ataxia (FA) comparing Single Dose: DT-216 with Placebo (2 arms). Primary endpoint: Frequency of treatment adverse events at 30 days. Started Mar 2022; status: completed.
02
Drugs
DT-216
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT05285540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285540.